The drug makers have pledged to publicly disclose their financial relationships with physicians. Their move anticipates the Physician Payments Sunshine Act that would mandate such reporting. The companies support a revised version of the legislation that preempts state gift-disclosure laws and would only require reporting of annual payments exceeding $500.